Genetic modifiers of Huntington's disease
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Huntington's disease (HD) is a devastating neurodegenerative disorder that directly affects more than 1 in 10,000 persons in Western societies but, as a family disorder with a long, costly, debilitating course, it has an indirect impact on a far greater proportion of the population. Although some palliative treatments are used, no effective treatment exists for preventing clinical onset of the disorder or for delaying its inevitable progression toward premature death, approximately 15 years after diagnosis. Huntington's disease involves a movement disorder characterized by chorea, as well as a variety of psychiatric disturbances and intellectual decline, with a gradual loss of independence. A dire need exists for effective HD therapies to alleviate the suffering and costs to the individual, family, and health care system. In past decades, genetics, the study of DNA sequence variation and its consequences, provided the tools to map the HD gene to chromosome 4 and ultimately to identify its mutation as an expanded CAG trinucleotide repeat in the coding sequence of a large protein, dubbed huntingtin. Now, advances in genetic technology offer an unbiased route to the identification of genetic factors that are disease‐modifying agents in human patients. Such genetic modifiers are expected to highlight processes capable of altering the course of HD and therefore to provide new, human‐validated targets for traditional drug development, with the goal of developing rational treatments to delay or prevent onset of HD clinical signs. © 2014 International Parkinson and Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Self-citationTrinucleotide repeat length instability and age of onset in Huntington's disease
Duyao, M., Ambrose, C., Myers, R., Novelletto, A., Persichetti, F., Frontali, M., Folstein, S., Ross, C., Franz, M., Abbott, M., et al. (1993) · Nature Genetics · doi:10.1038/ng0893-387 · Cited by 1,089
Self-citationTabrizi, S. J., Langbehn, D. R., Leavitt, B. R., Roos, R. A., Durr, A., Craufurd, D., Kennard, C., Hicks, S. L., Fox, N. C., Scahill, R. I., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70170-x · Cited by 984
The U.S.–Venezuela Collaborative Research Project*, & Wexler, N. S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308679101 · Cited by 761
Inactivation of the Mouse Huntington's Disease Gene Homolog Hdh
Duyao, M. P., Auerbach, A. B., Ryan, A., Persichetti, F., Barnes, G. T., McNeil, S. M., Ge, P., Vonsattel, J.-P., Gusella, J. F., Joyner, A. L., et al. (1995) · Science · doi:10.1126/science.7618107 · Cited by 723
Self-citationPinto, R. M., Dragileva, E., Kirby, A., Lloret, A., Lopez, E., St. Claire, J., Panigrahi, G. B., Hou, C., Holloway, K., Gillis, T., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003930 · Cited by 250 · cited 1×
“By contrast, genetic linkage has been successful in the mouse, using a knock-in model in which an expanded CAG repeat has been inserted in a genetically precise manner into the mouse huntingtin gene.(60) One of the HD-associated phenotypes common to both human and mouse is somatic instability of the CAG repeat in the…”
MethodFor the European Huntington Disease Network, Weydt, P., Soyal, S. M., Landwehrmeyer, G. B., & Patsch, W. (2014) · BMC Neurology · doi:10.1186/1471-2377-14-1 · Cited by 206 · cited 1×
“Although other SNPs at the locus have recently been proposed as modifiers, none yet meets the significance threshold of an unbiased search.(55,56) Genetic studies such as these can strongly implicate a protein as a potential therapeutic target in humans, but a negative result does not preclude the candidate from being…”
BackgroundPGC-1alphaas modifier of onset age in Huntington disease
Taherzadeh-Fard, E., Saft, C., Andrich, J., Wieczorek, S., & Arning, L. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-10 · Cited by 109 · cited 1×
“Investigation of several polymorphisms homed in on rs7665116, an intron variant that was reported to modify HD age at onset in three European HD cohorts.(51,52) However, analysis of the origins of cases that contributed to the effect revealed in a fourth study that individuals of Southern European origin have an incre…”
Cited by
Bates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., Nance, M., Ross, C. A., Scahill, R. I., Wetzel, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.5 · Cited by 1,641
Self-citationHuntington's disease: a clinical review
McColgan, P., & Tabrizi, S. J. (2018) · European Journal of Neurology · doi:10.1111/ene.13413 · Cited by 1,089
Identification of Genetic Factors that Modify Clinical Onset of Huntington’s Disease
Lee, J.-M., Wheeler, V. C., Chao, M. J., Vonsattel, J. P. G., Pinto, R. M., Lucente, D., Abu-Elneel, K., Ramos, E. M., Mysore, J. S., Gillis, T., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.003 · Cited by 655
“throughout life due to a completely dominant gain-of-function mechanism that leads after decades to onset of clinical signs (Gusella et al., 2014).”
Self-citationHuntington disease: new insights into molecular pathogenesis and therapeutic opportunities
Tabrizi, S. J., Flower, M. D., Ross, C. A., & Wild, E. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0389-4 · Cited by 538
(2018) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-63233-3.00017-8 · Cited by 122
Metadata
- Authors
- Gusella, J. F., MacDonald, M. E., & Lee, J.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2014-08-25
- Volume
- 29
- Issue
- 11
- Pages
- 1359-1365
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W1893983977
- Cited by
- 150
- References
- 8
- FWCI
- 5.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genetic modifiers of Huntington's disease. https://app.cochat.ai/papers/10.1002/mds.26001
- The paper
- Gusella, J. F., MacDonald, M. E., & Lee, J. (2014). Genetic modifiers of Huntington's disease. Movement Disorders. https://doi.org/10.1002/mds.26001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.